- /
- Supported exchanges
- / F
- / RGO.F
Regeneron Pharmaceuticals Inc (RGO F) stock market data APIs
Regeneron Pharmaceuticals Inc Financial Data Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies; and Tessera Therapeutics, Inc. to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Regeneron Pharmaceuticals Inc data using free add-ons & libraries
Get Regeneron Pharmaceuticals Inc Fundamental Data
Regeneron Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 14 248 M
- EBITDA: 4 348 M
- Earnings Per Share: 35
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2023-05-04
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Regeneron Pharmaceuticals Inc News
New
BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation
BrightInsight BrightInsight Expands Executive Leadership Team with Key HiresBrightInsight appoints three industry veterans to its Executive Leadership Team (ELT). Joining the company are Robert Zdon ...
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
BrightInsight SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight, a leader in digital health solutions, today announced a new investment round of $13 million from existing and new inve...
Should You Be Excited for Regeneron (REGN)?
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 3.35% in the quarter, com...
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Triggered look at Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals (...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.